All Programs

Use the tool below to view all available Series

Personalizing First-Line Therapy for CLL
Personalizing First-Line Therapy for CLL
CME/CE
Personalizing First-Line Therapy for CLL
William Wierda, MD, PhD; Matthew S. Davids, MD, MMSc
0.25 credits
- William Wierda, MD, PhD
- Matthew S. Davids, MD, MMSc
0.25 credits
Double-Class Refractory CLL in Community Practice: Current and Future Management
Double-Class Refractory CLL in Community Practice: Current and Future Management
CME/CE
Double-Class Refractory CLL in Community Practice: Current and Future Management
John C. Byrd, MD; William Mencia, MD, FACEHP
0.25 credits
- John C. Byrd, MD
- William Mencia, MD, FACEHP
0.25 credits
CME/CE In-Person Event
Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders
May 27, 2026
Miami Beach, Florida
1.00 credit
Treat-to-Target: Are We There Yet? 
Treat-to-Target: Are We There Yet? 
MinuteCE®
Treat-to-Target: Are We There Yet? 
Kimberly D. Orleck, PA-C; Jennifer Geremia, PA-C
1.00 program credit
- Kimberly D. Orleck, PA-C
- Jennifer Geremia, PA-C
1.00 program credit
Tailoring Treatment: Can You Select the Best Therapy? 
Tailoring Treatment: Can You Select the Best Therapy? 
MinuteCE®
Tailoring Treatment: Can You Select the Best Therapy? 
David Rubin, MD; Brooke Hodnick, PA-C, MPAS
1.00 program credit
- David Rubin, MD
- Brooke Hodnick, PA-C, MPAS
1.00 program credit
Case Review: Targets Are Met—Can You Stick the Landing? 
Case Review: Targets Are Met—Can You Stick the Landing? 
MinuteCE®
Case Review: Targets Are Met—Can You Stick the Landing? 
David Rubin, MD; Jennifer Geremia, PA-C
1.00 program credit
- David Rubin, MD
- Jennifer Geremia, PA-C
1.00 program credit
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?  
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?  
MinuteCE®
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?  
Kimberly D. Orleck, PA-C; Jennifer Geremia, PA-C
1.00 program credit
- Kimberly D. Orleck, PA-C
- Jennifer Geremia, PA-C
1.00 program credit
Remission: Can You Prove It? 
Remission: Can You Prove It? 
MinuteCE®
Remission: Can You Prove It? 
David Rubin, MD; Kimberly D. Orleck, PA-C
1.00 program credit
- David Rubin, MD
- Kimberly D. Orleck, PA-C
1.00 program credit
MinuteCE®
Clearing the Brain Fog: Innovations in the Treatment and Management of Hepatic Encephalopathy
Arun B. Jesudian, MD; Nancy S. Reau, MD
1.00 credit 9 episodes
- Arun B. Jesudian, MD
- Nancy S. Reau, MD
1.00 credit 9 episodes
Minimal Hepatic Encephalopathy: Hiding in Plain Sight?
Minimal Hepatic Encephalopathy: Hiding in Plain Sight?
MinuteCE®
Minimal Hepatic Encephalopathy: Hiding in Plain Sight?
Arun B. Jesudian, MD; Nancy S. Reau, MD
1.00 program credit
- Arun B. Jesudian, MD
- Nancy S. Reau, MD
1.00 program credit
Hepatic Encephalopathy: More Common Than You Think
Hepatic Encephalopathy: More Common Than You Think
MinuteCE®
Hepatic Encephalopathy: More Common Than You Think
Arun B. Jesudian, MD
1.00 program credit
- Arun B. Jesudian, MD
1.00 program credit
Minimal Hepatic Encephalopathy: A Covert Operation?
Minimal Hepatic Encephalopathy: A Covert Operation?
MinuteCE®
Minimal Hepatic Encephalopathy: A Covert Operation?
Nancy S. Reau, MD
1.00 program credit
- Nancy S. Reau, MD
1.00 program credit
Precision Treatment Pathways for MDD and Comorbid Insomnia
Precision Treatment Pathways for MDD and Comorbid Insomnia
CME/CE
Precision Treatment Pathways for MDD and Comorbid Insomnia
Michael E. Thase, MD
0.25 credits
- Michael E. Thase, MD
0.25 credits
Updates in Major Depressive Disorder with Insomnia
Updates in Major Depressive Disorder with Insomnia
CME/CE
Updates in Major Depressive Disorder with Insomnia
Michael E. Thase, MD; Andrew Krystal, MD
0.50 credits
- Michael E. Thase, MD
- Andrew Krystal, MD
0.50 credits
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
MinuteCE®
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
James M. Cleary, MD, PhD
0.50 program credits
- James M. Cleary, MD, PhD
0.50 program credits
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
MinuteCE®
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
James M. Cleary, MD, PhD
0.50 program credits
- James M. Cleary, MD, PhD
0.50 program credits

All Programs

Popular

Title